Skip to main content
. Author manuscript; available in PMC: 2014 Aug 14.
Published in final edited form as: Biol Psychiatry. 2012 Nov 28;73(12):1156–1163. doi: 10.1016/j.biopsych.2012.09.031

Table 1. Scopolamine Response vs. Remission (Rates Based on MADRS)a.

Diagnosis Response (≥50% Improvement) Remission (Mean of Final Two Sessions ≤10)
MDD
n/ntotal (%) 26/38 (68) 18/38 (47)
BD
n/ntotal (%) 10/15 (67) 9/15 (60)

BD, bipolar disorder; MADRS, Montgomery-Åsberg Depression Rating Scale; MDD, major depressive disorder.

a

One BD and no MDD subjects met response criteria to placebo.